Taysha Gene Therapies (TSHA) risk factors, FY2024 10-K

Other

1. 01Selected Risks Affecting Our Business
2. 02We have a limited operating history and no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability
3. 03We intend to identify and develop novel gene therapy product candidates, which makes it difficult to predict the time, cost and potential success of product candidate development
4. 04Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business
5. 05UT Southwestern has entered into collaborations with third parties, including certain of our competitors, addressing targets and disease indications outside the scope of our collaboration. As a result, UT Southwestern may have competing interests with respect to their priorities and resources
6. 06We may be subject to legal proceedings from time to time which seek material damages

Risks Related to our Financial Position and Capital Needs

1. 07We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability
2. 08incur additional legal, accounting and other expenses in operating as a public company
3. 09We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will need to develop commercial capabilities, and we may not be successful in doing so
4. 10the costs of operating as a public company
5. 11Our existing indebtedness contains restrictions that potentially limit our flexibility in operating our business. In addition, we may be required to make a prepayment or repay our outstanding indebtedness earlier than we expect under our Trinity Term Loan Agreement if we are unable to satisfy certain conditions
6. 12enter into material transactions with affiliates
7. 13At closing, we drew the full $40.0 million
8. 14Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
9. 15Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations

Risks Related to the Development of our Product Candidates

1. 16TSHA-102 is currently our lead product candidate and there is no guarantee that we will be able to successfully develop and commercialize TSHA-102
2. 17maintaining a continued acceptable safety, tolerability and efficacy profile of the products following approval
3. 18Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop
4. 19Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates
5. 20foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates
6. 21manufacturing sufficient quantities of product candidate for use in clinical trials
7. 22any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us
8. 23have the product removed from the market after obtaining marketing approval
9. 24The regulatory approval processes of the FDA, European Commission and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed
10. 25We have not yet completed testing of any product candidate in clinical trials. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials
11. 26Interim “top-line” and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
12. 27our reputation and physician or patient acceptance of our products may suffer
13. 28As an organization, we have never conducted pivotal clinical trials, and may be unable to do so for any product candidates we may develop, including TSHA-102
14. 29The disorders we seek to treat have low prevalence and it may be difficult to identify and enroll patients with these disorders. If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented
15. 30the proximity and availability of clinical trial sites for prospective patients
16. 31We may seek orphan drug designation for some of our product candidates and we may be unsuccessful, or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity, for product candidates for which we obtain orphan drug designation
17. 32We have received rare pediatric disease designation for TSHA-102 for the treatment of Rett syndrome. However, a marketing application for TSHA-102, if approved, may not meet the eligibility criteria for a PRV or the rare pediatric disease designation program may sunset before FDA is able to consider us for a voucher
18. 33the BLA is approved for a different adult indication than the rare pediatric disease for which TSHA-102 is designated
19. 34We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
20. 35We may not be successful in our efforts to build a pipeline of additional product candidates
21. 36If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed

Risks Related to the Manufacturing of our Product Candidates

1. 37Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business
2. 38The manufacture of gene therapy products is technically complex and necessitates substantial expertise and capital investment. Production difficulties caused by unforeseen events may delay the availability of material for our clinical studies
3. 39We and our contract manufacturers for AAV9 are subject to significant regulation with respect to manufacturing our products. The third-party manufacturing facilities on which we rely may have limited capacity or fail to meet the applicable stringent regulatory requirements
4. 40We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business
5. 41Any contamination or interruption in our manufacturing process, shortages of raw materials or failure of our suppliers of plasmids and viruses to deliver necessary components could result in delays in our clinical development or marketing schedules
6. 42Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay

Risks Related to the Commercialization of our Product Candidates

1. 43Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
2. 44Negative public opinion of gene therapy and increased regulatory scrutiny of gene therapy and genetic research may adversely impact the development or commercial success of our current and future product candidates
3. 45If we are unable to establish sales, marketing and distribution capabilities for TSHA-102 or any other product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates if and when they are approved
4. 46unforeseen costs and expenses associated with creating an independent sales and marketing organization
5. 47The affected populations for our other product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates
6. 48We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively
7. 49successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new medicines
8. 50Biologic products may face competition sooner than anticipated
9. 51The success of our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients to pay for these procedures
10. 52Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
11. 53the inability to commercialize any products that we may develop

Risks Related to Our Dependence on Third Parties

1. 54We intend to rely on third parties to conduct a significant portion of our existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials
2. 55We may seek collaborations with third parties for the development or commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates
3. 56collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates

Risks Related to our Intellectual Property

1. 57If we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market
2. 58If we fail to comply with our obligations in our current and future intellectual property licenses with third parties, we could lose rights that are important to our business
3. 59Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our future patents
4. 60We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful
5. 61We may be unsuccessful in licensing or acquiring intellectual property from third parties that may be required to develop and commercialize our product candidates
6. 62Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain
7. 63We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties
8. 64We may be subject to claims challenging the inventorship or ownership of our future patents and other intellectual property
9. 65Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
10. 66We may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
11. 67Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
12. 68Any trademarks we have obtained or may obtain may be infringed or otherwise violated, or successfully challenged, resulting in harm to our business
13. 69Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Legal and Regulatory Compliance Matters

1. 70Even if we obtain regulatory approval for TSHA-102 or any future product candidates, they will remain subject to ongoing regulatory oversight
2. 71withdrawal of marketing approval. We will further be required to immediately report any serious and unexpected adverse events and certain quality or production problems with our products to regulatory authorities along with other periodic reports
3. 72refuse to allow us to enter into supply contracts, including government contracts
4. 73In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy
5. 74Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations
6. 75additional recordkeeping
7. 76If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, our development plans may be impacted

Risks Related to Employee Matters and Managing our Growth

1. 77Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel, and recent changes to our team might harm future operating results
2. 78Our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements

Risks Related to Ownership of our Common Stock

1. 79The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses
2. 80other events or factors, many of which are beyond our control
3. 81If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
4. 82Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to drop significantly, even if our business is doing well
5. 83An active trading market for our common stock may not continue to be developed or sustained
6. 84Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result
7. 85stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder meetings
8. 86Concentration of ownership of our common stock among our principal stockholders may prevent new investors from influencing significant corporate decisions
9. 87We are an “emerging growth company” and a “smaller reporting company” and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors
10. 88not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved
11. 89We have broad discretion in the use our cash and cash equivalents
12. 90Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment
13. 91any action asserting a claim against us that is governed by the internal-affairs doctrine
14. 92We have a limited number of unreserved, authorized shares

General Risks

1. 93actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences
2. 94States. Other jurisdictions have enacted or are considering similar cross-border personal data transfer laws and local personal data residency laws, any of which could increase the cost and complexity of doing business
3. 95actions; litigation; fines and penalties; disruptions to our operations such as our clinical trials; claims that we breached our data privacy and security laws; reputational harm; a loss of customers or sales; and other adverse consequences
4. 96and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program
5. 97Our business activities will be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws
6. 98We are obligated to maintain proper and effective internal controls over financial reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock
7. 99Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts
8. 100We might not be able to utilize a significant portion of our net operating loss carryforwards
9. 101New tax laws or regulations, changes to existing tax laws or regulations or changes in their application to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations
10. 102We have incurred and will continue to incur increased costs and demands upon management as a result of being a public company